CAJ | 학술논문

目的：探讨傣药牙帕汤对小鼠Lewis肺癌的抑制作用及其对小鼠免疫功能的影响。方法C57BL/6小鼠右腋皮下注射Lewis肺癌细胞（lewislungcarcinoma，LLC），采用随机双盲法（随机抽取仅留有一侧开口的密闭黑盒子中的30只雄性小鼠，放入事先备好的6个鼠笼中，雌性小鼠依此法进行分组），将接种的60只小鼠分为空白对照组、牙帕汤高、中、低剂量组、环磷酰胺组、牙帕汤与环磷酰胺联合组各10只。各组均从接种后第3天给药，空白对照组、牙帕汤高、中、低剂量组按0.4ml/（只?d）分别灌胃，给予0.9%生理盐水、高、中、低浓度的牙帕汤；环磷酰胺组每隔2d腹腔注射环磷酰胺0.2ml/只；牙帕汤与环磷酰胺联合组按0.4ml/（只?d）灌胃给予中剂量牙帕汤、每隔2d按0.2ml/只腹腔注射环磷酰胺。第21天，摘眼球取血，取肿瘤组织、脾、胸腺并称重，计算抑瘤率、脾指数和胸腺指数；采用酶联免疫吸附法检测血清中白细胞介素-2（IL-2）、白细胞介素-10（IL-10）含量。结果牙帕汤高剂量组、环磷酰胺组、牙帕汤与环磷酰胺联合组的瘤重分别为（3.46±0.39）g、（2.39±1.04）g、（2.30±0.76）g，均低于空白对照组（5.21±0.50）g，差异均有统计学意义（P＜0.05），抑瘤率分别为33.69%、54.12%、56.00%；牙帕汤低、中、高各剂量组的胸腺指数分别为（2.16±0.69）、（2.24±0.76）、（2.23±0.63），脾指数分别为（16.82±3.14）、（15.82±1.72）、（17.08±3.65），均高于空白对照组（1.94±0.68）、（15.17±3.53）；环磷酰胺组（1.72±0.58）、（14.82±3.78）下降较明显。与空白对照组比较，各给药组的肺转移灶数目均降低，但差异无统计学意义（P＞0.05）。空白对照组IL-2、IL-10分别为（883.54±181.49）ng/L、（1106.86±343.79）ng/L，牙帕汤低、中、高各剂量组的IL-2水平明显提高，分别为（1732.29±100.52）ng/L、（1813.33±168.32）ng/L、（2275.63±394.76）ng/L；IL-10分别为（834.02±271.97）ng/L、（636.83±270.56）ng/L、（682.08±147.85）ng/L水平显著降低。结论牙帕汤可以抑制Lewis肺癌细胞生长，降低肺转移灶数目，调节免疫细胞因子IL-2、IL-10的表达水平。目的：探討傣藥牙帕湯對小鼠Lewis肺癌的抑製作用及其對小鼠免疫功能的影響。方法C57BL/6小鼠右腋皮下註射Lewis肺癌細胞（lewislungcarcinoma，LLC），採用隨機雙盲法（隨機抽取僅留有一側開口的密閉黑盒子中的30隻雄性小鼠，放入事先備好的6箇鼠籠中，雌性小鼠依此法進行分組），將接種的60隻小鼠分為空白對照組、牙帕湯高、中、低劑量組、環燐酰胺組、牙帕湯與環燐酰胺聯閤組各10隻。各組均從接種後第3天給藥，空白對照組、牙帕湯高、中、低劑量組按0.4ml/（隻?d）分彆灌胃，給予0.9%生理鹽水、高、中、低濃度的牙帕湯；環燐酰胺組每隔2d腹腔註射環燐酰胺0.2ml/隻；牙帕湯與環燐酰胺聯閤組按0.4ml/（隻?d）灌胃給予中劑量牙帕湯、每隔2d按0.2ml/隻腹腔註射環燐酰胺。第21天，摘眼毬取血，取腫瘤組織、脾、胸腺併稱重，計算抑瘤率、脾指數和胸腺指數；採用酶聯免疫吸附法檢測血清中白細胞介素-2（IL-2）、白細胞介素-10（IL-10）含量。結果牙帕湯高劑量組、環燐酰胺組、牙帕湯與環燐酰胺聯閤組的瘤重分彆為（3.46±0.39）g、（2.39±1.04）g、（2.30±0.76）g，均低于空白對照組（5.21±0.50）g，差異均有統計學意義（P＜0.05），抑瘤率分彆為33.69%、54.12%、56.00%；牙帕湯低、中、高各劑量組的胸腺指數分彆為（2.16±0.69）、（2.24±0.76）、（2.23±0.63），脾指數分彆為（16.82±3.14）、（15.82±1.72）、（17.08±3.65），均高于空白對照組（1.94±0.68）、（15.17±3.53）；環燐酰胺組（1.72±0.58）、（14.82±3.78）下降較明顯。與空白對照組比較，各給藥組的肺轉移竈數目均降低，但差異無統計學意義（P＞0.05）。空白對照組IL-2、IL-10分彆為（883.54±181.49）ng/L、（1106.86±343.79）ng/L，牙帕湯低、中、高各劑量組的IL-2水平明顯提高，分彆為（1732.29±100.52）ng/L、（1813.33±168.32）ng/L、（2275.63±394.76）ng/L；IL-10分彆為（834.02±271.97）ng/L、（636.83±270.56）ng/L、（682.08±147.85）ng/L水平顯著降低。結論牙帕湯可以抑製Lewis肺癌細胞生長，降低肺轉移竈數目，調節免疫細胞因子IL-2、IL-10的錶達水平。
목적：탐토태약아파탕대소서Lewis폐암적억제작용급기대소서면역공능적영향。방법C57BL/6소서우액피하주사Lewis폐암세포（lewislungcarcinoma，LLC），채용수궤쌍맹법（수궤추취부류유일측개구적밀폐흑합자중적30지웅성소서，방입사선비호적6개서롱중，자성소서의차법진행분조），장접충적60지소서분위공백대조조、아파탕고、중、저제량조、배린선알조、아파탕여배린선알연합조각10지。각조균종접충후제3천급약，공백대조조、아파탕고、중、저제량조안0.4ml/（지?d）분별관위，급여0.9%생리염수、고、중、저농도적아파탕；배린선알조매격2d복강주사배린선알0.2ml/지；아파탕여배린선알연합조안0.4ml/（지?d）관위급여중제량아파탕、매격2d안0.2ml/지복강주사배린선알。제21천，적안구취혈，취종류조직、비、흉선병칭중，계산억류솔、비지수화흉선지수；채용매련면역흡부법검측혈청중백세포개소-2（IL-2）、백세포개소-10（IL-10）함량。결과아파탕고제량조、배린선알조、아파탕여배린선알연합조적류중분별위（3.46±0.39）g、（2.39±1.04）g、（2.30±0.76）g，균저우공백대조조（5.21±0.50）g，차이균유통계학의의（P＜0.05），억류솔분별위33.69%、54.12%、56.00%；아파탕저、중、고각제량조적흉선지수분별위（2.16±0.69）、（2.24±0.76）、（2.23±0.63），비지수분별위（16.82±3.14）、（15.82±1.72）、（17.08±3.65），균고우공백대조조（1.94±0.68）、（15.17±3.53）；배린선알조（1.72±0.58）、（14.82±3.78）하강교명현。여공백대조조비교，각급약조적폐전이조수목균강저，단차이무통계학의의（P＞0.05）。공백대조조IL-2、IL-10분별위（883.54±181.49）ng/L、（1106.86±343.79）ng/L，아파탕저、중、고각제량조적IL-2수평명현제고，분별위（1732.29±100.52）ng/L、（1813.33±168.32）ng/L、（2275.63±394.76）ng/L；IL-10분별위（834.02±271.97）ng/L、（636.83±270.56）ng/L、（682.08±147.85）ng/L수평현저강저。결론아파탕가이억제Lewis폐암세포생장，강저폐전이조수목，조절면역세포인자IL-2、IL-10적표체수평。
Objective To study the Dai medicine Yapa Tang inhibition on mice Lewis lung carcinoma growth and metastasis,and to explore the impact of the drug on mice immune function. Methods Subcutaneous injection LLC(Lewis lung carcinoma cells)in C57BL/6 mice’s right armpit was to establish rat models. 60 successful tumor-bearing mice were selected and thenafter inoculating LLC were randomly divided into 6 groups, namely the control group,Yapa Tang low-dose group,Yapa Tang mid-dose group, Yapa Tang high-dose group,cyclophosphamide group and Yapa Tang mid-dose combining cyclophosphamide group.Then,after inoculated 3 days,each group was administrated with medicines.The first four groups wereintragastricly administrated with 0.9% saline, low-dose, mid-dose and high-dose Yapa Tang with0.4ml respectively;the cyclophosphamide group was administrated with cyclophosphamide,and Yapa Tang mid-dose combining cyclophosphamide group was administrated with middle dose Yapa Tang and cyclophosphamide. After 21days, blood was taken from eyeballs. Tumor tissue, spleen, thymus were gotten and weighted to calculate inhibitory rate,spleen and thymus index, enzyme-linked immunosorbent assay (Elisa) was adopted to detect Interleukin-2(IL-2), Interleukin-10(IL-10)and their contents. Results The tumor weight of Yapa Tang high-dose group, cyclophosphamide group and Yapa Tang mid-dose combining cyclophosphamide group was 3.46±0.39, 2.39±1.04 and 2.30±0.76 respectively,all lower than the control group, which was 5.21±0.50, showing significant difference(P<0.05), with the inhibition rate were33.69%, 54.12%, 56.00%. The thymus and spleen index of Yapa Tang low-dose group, middle-dose group and high-dose group was2.16±0.69, 2.24± 0.76, 2.23 ± 0.63, 16.82 ± 3.14, 15.82 ± 1.72, 17.08 ± 3.65, significantly higher than that of the control group,which was1.94±0.6, 15.17±3.53. The IL-2, IL-10 level of control group were(883.54±181.49)ng/L, (1 106.86±343.79)ng/L. Yapa Tanggroupsshowed an increase in IL-2(1 732.29±100.52)ng/L, (1 813.33± 168.32)ng/L, (2 275.63 ± 394.76)ng/L and the decrease in level of IL-10, respectively were(834.02 ± 271.97)ng/L, (636.83±270.56)ng/L, (682.08±147.85)ng/L, with significant difference. Conclusion Yapa Tang can inhibit lewis lung cancer grow and reduce the number of lung metastases, regulate immune cytokines IL-2 and IL-10, and promote the immunity of tumor-bearing mice.